Carbohydrate-based therapeutics
Record details
- ISBN: 9783527348701 (hardcover)
-
Physical Description:
xvii, 390 pages : illustrations (some color) ; 26 cm
print - Publisher: Weinheim : Wiley-VCH, [2024].
- Copyright: ©2024
Content descriptions
Bibliography, etc. Note: | Includes bibliographical references and index. |
Formatted Contents Note: | Introduction -- DC-SIGN Ligands Employing Natural Carbohydrate Epitopes -- Dendrimers -- Nanoparticles -- Polymers -- Other Multivalent Scaffolds -- DC-SIGN Ligands Employing Carbohydrate Derivatives or Glycomimetics -- Conclusion and Perspectives -- The Bacterial Adhesin FimH -- UTIs and FimH -- FimH CRD -- FimH Antagonists -- Conclusion and Perspectives -- Pseudomonas aeruginosa Virulence Factors (PA-IL and PA-IIL) -- Introduction -- Mono- and Oligovalent Glycomimetic PL-Ligands -- Conclusions and Perspectives -- General Aspects -- References -- Targeting Carbohydrates in Cancer - Analytical and Biotechnological Tools -- Aberrant Protein Glycosylation in Cancer -- Detection and Mapping of Carbohydrate-Based Antigens in Human Neoplastic Tissues -- Imaging Mass Spectrometry -- In Situ Proximity Ligation Assay -- Glycan Microarrays -- Glycoengineered In Vitro, In Vivo, and Ex Vivo Models -- Structural Elucidation of Glycoconjugates: Glycomic and Glycoproteomic Strategies -- Concluding Remarks -- List of Abbreviations -- References -- Carbohydrate-Specific Monoclonal Antibody Therapeutics -- Introduction -- Types of Monoclonal Antibodies -- IgG Antibodies -- IgM Antibodies -- ScFv and Fab Fragments -- Humanization of Monoclonal Antibodies -- CDR Grafting -- Transgenic Animals -- Breakthrough Research -- mAbs from Preclinical to Clinical Studies -- Globo Series -- Blood Group -- Mucin-Attached Glycans -- New Treatment Options for Neuroblastoma -- History of Unituxin -- What is Unituxin? -- Challenges with Unituxin -- A mAbs Binding to Neuroblastoma -- Chimeric and Humanized Anti-GD2 Antibodies -- Naxitamab as a Potential Alternative for High-Risk Patients -- Chimeric Antigen Receptors (CARs) Targeting GD2 -- Summary -- List of Abbreviations -- References -- Carbohydrates in Tissue Engineering -- Introduction -- Biomaterials and Medical Devices: Natural and Synthetic Strategies -- Carbohydrates as Building Blocks for Medical Device Formulation -- Human Polysaccharides: Glycosaminoglycans (GAGs) and Proteoglycans (PGs) -- Polysaccharides from Plants, Algae, Animal, and Microbial Fermentation -- Carbohydrates as Signaling Molecules: Opportunities in Tissue Engineering and Regenerative Medicine -- Carbohydrates in Animal-Derived Medical Devices: Friends or Foes? -- Glycoengineering Application to Regenerative Medicine -- Future Opportunities and Major Challenges -- Conflict of Interest -- References -- Carbohydrate-Based Therapeutics for Lysosomal Storage Disorders -- An Introduction to Lysosomal Storage Disorders (LSDs) -- Available Treatments for LSDs: The Role of Carbohydrate-Based Therapeutics -- Enzyme Replacement Therapy (ERT) -- Substrate Reduction Therapy (SRT) -- Pharmacological Chaperone Therapy (PCT) -- Combined ERT/PC Therapy -- Mucopolysaccharidoses -- Sphingolipidoses -- Fabry Disease -- Gaucher Disease -- Niemann-Pick -- GM1 Gangliosidosis and Morquio B (β-Gal) -- GM2 Gangliosidosis (β-Hexosaminidase) -- Krabbe -- Glycogen Storage Disorders -- Pompe Disease -- Glycoproteinoses -- Fucosidosis -- α-Mannosidosis -- Conclusions -- Acknowledgments -- Abbreviations and Acronyms -- References -- Carbohydrates and Carbohydrate-Based Therapeutics in Alzheimer's Disease -- Introduction -- O-GlcNAc Transferase (OGT) and O-GlcNAc Hydrolase (OGA) in Neurodegeneration -- O-GlcNAc Cycling as a Therapeutic Target Against Alzheimer's Amyloid Plaques and Neurofibrillary Tangles -- OGA Inhibitors -- PUGNAc -- GlcN Acstatins -- Thiazoline Inhibitors -- GalNAc in Neurodegeneration -- Chitosan and Derivatives in AD Brain -- Cholinesterase Inhibitors -- Fyn Kinase Inhibitors -- Amyloid Protein-Protein Interaction Inhibitors -- Inhibitors of Aβo and/or Oxidative Stress-Induced Neurotoxicity -- Carbohydrate-Protein Interactions as Potential Therapeutic Targets Against AD -- Lipid-Raft Gangliosides as Membrane Accumulation Sites for Toxic Aβ Aggregates -- The Role of Microglial Cells in Aβ Brain Clearance -- Conclusion -- List of Abbrev iations -- Acknowledgments -- References -- Carbohydrate-Based Antithrombotics -- Introduction -- Antithrombotic Drugs -- Heparin -- Mechanism of Interaction with Coagulation Factors -- Antithrombin-Mediated Activity -- Heparin Cofactor II Mediated Activity -- Additional Factors -- Adverse Effects of Heparin -- Heparin-Induced Thrombocytopenia -- Osteoporosis -- Low Molecular Weight Heparins -- Ultralow Molecular Weight Heparins -- Drugs Based on Natural GAG Mixtures -- The Role of Dermatan Sulfate -- Sulodexide -- Danaparoid -- Mesoglycan -- Defibrotide -- Pentosan Polysulfate -- Fondaparinux and Related Synthetic Oligosaccharides -- Chemoenzymatic Synthesis of Oligosaccharides -- Conclusions and Perspectives -- Acknowledgment -- References -- Index. |
Search for related items by subject
Subject: | Carbohydrates -- Therapeutic use Materia medica Drug development |
Available copies
- 1 of 1 copy available at University College of the North Libraries.
Holds
- 0 current holds with 1 total copy.
Show Only Available Copies
Location | Call Number / Copy Notes | Barcode | Shelving Location | Holdable? | Status | Due Date |
---|---|---|---|---|---|---|
The Pas Campus Library | RM 301.25 .C373 2024 (Text) | 58500001239987 | Stacks | Volume hold | Available | - |